Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 22, 2006

Roche Terminates Daclizumab Deal with PDL BioPharma

  • Roche discontinued its agreement with PDL BioPharma to jointly develop and commercialize Daclizumab for organ transplant patients. Roche made this decision subsequent to a review of its development programs. The co-development agreement between PDL and Roche will formally terminate in May.

    As a result, PDL will hold exclusive development and commercial rights to Daclizumab for transplant maintenance.
    "We are evaluating the overall transplant maintenance indication opportunity for daclizumab, while we continue to support the ongoing studies of daclizumab in relapsing/remitting multiple sclerosis, and anticipate results from the ongoing Phase II study, which is testing daclizumab in combination with beta-interferon, during 2007," said Mark McDade, CEO, PDL BioPharma. "In the meantime, efforts are ongoing to evaluate partnership opportunities for this important drug in asthma."



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »